Dividends4Life: Abbvie Inc. (ABBV) Dividend Stock Analysis

Dividend Growth Stocks News

Abbvie Inc. (ABBV) Dividend Stock Analysis

Posted by D4L | Thursday, July 20, 2023 | | 0 comments »

Linked here is a detailed quantitative analysis of Abbvie Inc. (ABBV). Below are some highlights from the above linked analysis: Company Description: Abbvie Inc. is a global research-based pharmaceuticals business that emerged as a separate entity following its spin-off from Abbott Laboratories at the start of 2013. AbbVie's key drug is Humira for rheumatoid arthritis.

Peers: The company's peer group includes: Merck & Co. Inc. (MRK) with a 2.7% yield, Bristol-Myers Squibb Company (BMY) with a 3.5% yield, and Eli Lilly & Co. (LLY) with a 1.0% yield. Conclusion: ABBV earned one Star in the Fair Value section, earned two Stars in the Dividend Analytical Data section and earned one Star in the Dividend Income vs. MMA section for a total of four Stars. This quantitatively ranks ABBV as a...

Source: Dividend Growth Stocks

Related Articles:



Post a Comment

Note: Only a member of this blog may post a comment.